Castelli risk index I

There are 28 papers on Castelli risk index I in aging research: 12 trials and 16 observational studies in people.

Biomarker

28 papers study it4 more mention it6 findings

4 new papers in 30 daysSee all 32 papers on Castelli risk index I

“After full adjustment, higher CRI-I levels were associated with progressively lower odds of sarcopenia.”
Machine learning evaluation of the discriminative ability of Castelli Risk Index-I and other non-traditional lipid indices for sarcopenia: a cross-sectional study based on CHARLSLipids in health and disease2026doi:10.1186/s12944-026-02892-8
  • Human trial12
  • Humans16

Interventions

3

Resveratrol

no changein humans1

1 study
  1. Resveratrol showed no clear effect on Castelli risk index I in humans (− 0.25 ± 0.9 vs. − 0.09 ± 0.5).

    “After adjusting for confounding variables (medications, diabetes duration, energy intake and physical activity), no significant difference was also revealed in mean changes of LAP (− 2.46 ± 23.3 vs. 1.43 ± 14.3; P = 0.43), VAI (− 0.25 ± 1.1 vs. − 0.02 ± 0.6; P = 0.47), CRI-I (− 0.25 ± 0.9 vs. − 0.09 ± 0.5; P = 0.79”

    Human trial8 weeksn = 76

    Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial

    BMC cardiovascular disorders

  2. Resveratrol showed no clear effect on Castelli risk index I in humans (overweight type 2 diabetes) (mean change: - 0.25 ± 0.9 vs. - 0.09 ± 0.5; P = 0.79).

    “no significant difference was found between the intervention group and the control group in LAP”

    Human trialoverweight type 2 diabetes1000 mg/day8 weeksn = 71

    Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial

    BMC cardiovascular disorders

More on Resveratrol

Exercise

downin humans1

1 study
  1. Exercise decreases Castelli risk index I in humans (sedentary middle-aged women) (-11.7%, p < 0.001).

    “Castelli risk index I (−11.7%, p < 0.001), and Castelli risk index II (−14.6%, p < 0.001)”

    Human trialsedentary middle-aged women20-weekfemalesn = 15

    Effects of Individualized Periodized Combined Training on Lipid Profile and Atherogenic Cardiovascular Risk in Sedentary Middle-aged Colombian Women

    World Journal of Public Health

More on Exercise

Taurine

downin humans1

1 study
  1. Taurine decreases Castelli risk index I in humans (before and after incremental exercise in heart failure patients).

    “Our results also show that atherogenic indices [Castelli's Risk Index-I (CRI-I), Castelli's Risk Index-II (CRI-II) and Atherogenic Coefficient (AC)] decreased in the taurine group”

    Human trialbefore and after incremental exercise in heart failure patients500 mg three times a day2 weeks

    Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure

    Therapeutic advances in cardiovascular disease

More on Taurine

Associations

2

Cardiovascular and cerebrovascular disease mortality

upin humans1HR 1.35

1 study
  1. Castelli risk index I predicts cardiovascular and cerebrovascular disease mortality in humans (type 2 diabetes mellitus) (HR: 1.35, 95% CI: 1.02 - 1.78, p = 0.038).

    “The -CRI-I predicted CCVD deaths in elderly T2DM patients (HR: 1.35, 95% CI: 1.02 - 1.78, p = 0.038) after fully adjusting for age, gender, smoking, drinking”

    Humanstype 2 diabetes mellitus7.62 yearsn = 888

    Association between Castelli risk index and cardiovascular and cerebrovascular mortality in elderly type 2 diabetes mellitus patients

    Biomarkers in medicine

Sarcopenia

downin humans1

1 study
  1. Castelli risk index I is associated with sarcopenia in humans after full adjustment.

    “After full adjustment, higher CRI-I levels were associated with progressively lower odds of sarcopenia.”

    Humansafter full adjustment

    Machine learning evaluation of the discriminative ability of Castelli Risk Index-I and other non-traditional lipid indices for sarcopenia: a cross-sectional study based on CHARLS

    Lipids in health and disease

More on Sarcopenia

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 4Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 1Aug 2026: 2Sep 2026: 3Oct 2026: 4Nov 2026: 120 papers in 12 months

See all 32 papers on Castelli risk index I